Jury Delivers Verdict After Month-Long Trial (Image Credits: Pexels)
Chicago, Illinois – A Cook County Circuit Court jury handed Abbott Laboratories a major setback last week by awarding $53 million in compensatory damages to the mothers of four premature infants who developed necrotizing enterocolitis (NEC) following exposure to the company’s Similac Special Care formula.[1][2] The court later tacked on $17 million in punitive damages, pushing the total liability to $70 million. Abbott quickly signaled its intent to challenge the decision through an appeal process.[3]
Jury Delivers Verdict After Month-Long Trial
The decision came at the end of an intensive month-long trial in Cook County. Jurors determined that Abbott bore responsibility on three key counts: product defect, failure to warn healthcare providers adequately, and general negligence. The plaintiffs argued that their babies contracted NEC while hospitalized and fed the cow’s milk-based preterm formula designed for premature infants.
Individual awards varied among the four families. One mother received $16 million, two others got $15 million each, and the fourth was granted $9 million. These compensatory sums addressed the profound losses tied to the infants’ severe intestinal condition, which can prove life-threatening in vulnerable preterm newborns.[1]
- $16 million to one family
- $15 million to a second family
- $15 million to a third family
- $9 million to the fourth family
The punitive portion arrived on Friday, April 10, underscoring the jury’s view of Abbott’s conduct. This ruling marks another chapter in ongoing scrutiny of infant nutrition products for high-risk neonates.
Abbott Rejects Findings, Cites Scientific Consensus
Abbott Laboratories responded swiftly to the verdict. Company representatives expressed strong disagreement, pointing to broad medical and regulatory support for the safety of preterm nutritionals. “We stand by the safety of these products and the vital role they play,” the firm stated. “In light of verdicts like this, and as we have repeatedly said, if the regulatory process and science is going to be disregarded, it’s going to be very difficult for any company to remain on the US market with these products.”[1]
Abbott highlighted prior courtroom successes, including four victories. One notable win occurred in October 2024 in the northern district of Illinois eastern division, where a court rejected claims linking Similac Special Care 24 to a baby’s NEC-related death. The company maintains that no reliable evidence connects its formulas to NEC causation.
Plans for appeal focus on these scientific and regulatory alignments. Abbott views the outcome as misaligned with expert consensus on the necessity of such products for preterm care.
Surge of NEC-Related Litigation Against Formula Makers
NEC lawsuits have proliferated against Abbott in recent years. As of late January 2025, approximately 1,490 cases lingered in federal and state courts nationwide. Some federal rulings have dismissed claims, affirming the essential role of preterm formulas and labeling attacks on them as unsubstantiated.[1]
Past verdicts paint a mixed picture. A table below summarizes select outcomes:
| Location | Date | Award Amount | Result for Abbott |
|---|---|---|---|
| St. Louis state court | 2024 | $495 million ($95m compensatory + $400m punitive) | Loss |
| Northern District of Illinois | October 2024 | None | Win |
| Cook County, Illinois | April 2026 | $70 million | Loss (appeal pending) |
Such cases often center on allegations that cow’s milk formulas heighten NEC risks compared to human milk alternatives in neonatal intensive care units. Abbott and peers defend their products as medically endorsed lifelines for infants unable to breastfeed.
Stakes Rise for Preterm Nutrition Market
This latest verdict amplifies pressures on the infant formula sector. Abbott’s appeal rhetoric signals broader concerns: diverging from established science could jeopardize availability of specialized preterm feeds. Regulators and physicians continue to endorse these items despite litigation waves.
The cases spotlight tensions between parental claims, emerging research debates, and industry necessities. With thousands of suits in play, future appeals and potential settlements may reshape product labeling, marketing, and hospital protocols.
Observers watch closely as Abbott mounts its defense. The appeal could test boundaries between jury decisions and scientific benchmarks in product liability arenas.[2][3]
Key Takeaways
- A Chicago jury awarded $53 million compensatory plus $17 million punitive damages to four families in an NEC formula case against Abbott.
- Abbott disputes the science behind the claims and plans a vigorous appeal.
- NEC litigation persists with over 1,400 cases pending, yielding mixed verdicts for the company.
As appeals unfold, this case underscores the delicate balance in neonatal care innovation and accountability. What implications do you see for infant formula safety standards? Share your thoughts in the comments.
